As of 2025-10-19, the Relative Valuation of Intellia Therapeutics Inc (NTLA) is (62.18) USD. This relative valuation is based on P/E multiples. With the latest stock price at 24.75 USD, the upside of Intellia Therapeutics Inc based on Relative Valuation is -351.2%.
The range of the Relative Valuation is (61.64) - (62.71) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 14.0x | 13.9x |
| Forward P/E multiples | 13.7x - 14.1x | 13.9x |
| Fair Price | (61.64) - (62.71) | (62.18) |
| Upside | -349.1% - -353.4% | -351.2% |
| Date | P/E |
| 2025-10-17 | -5.53 |
| 2025-10-16 | -5.57 |
| 2025-10-15 | -5.80 |
| 2025-10-14 | -5.34 |
| 2025-10-13 | -5.31 |
| 2025-10-10 | -5.48 |
| 2025-10-09 | -5.69 |
| 2025-10-08 | -5.47 |
| 2025-10-07 | -4.57 |
| 2025-10-06 | -4.59 |
| 2025-10-03 | -4.46 |
| 2025-10-02 | -4.57 |
| 2025-10-01 | -4.19 |
| 2025-09-30 | -3.86 |
| 2025-09-29 | -3.78 |
| 2025-09-26 | -3.65 |
| 2025-09-25 | -3.71 |
| 2025-09-24 | -3.97 |
| 2025-09-23 | -3.82 |
| 2025-09-22 | -3.86 |
| 2025-09-19 | -3.49 |
| 2025-09-18 | -3.60 |
| 2025-09-17 | -2.77 |
| 2025-09-16 | -2.74 |
| 2025-09-15 | -2.59 |
| 2025-09-12 | -2.55 |
| 2025-09-11 | -2.55 |
| 2025-09-10 | -2.52 |
| 2025-09-09 | -2.66 |
| 2025-09-08 | -2.65 |
| 2025-09-05 | -2.70 |
| 2025-09-04 | -2.60 |
| 2025-09-03 | -2.62 |
| 2025-09-02 | -2.55 |
| 2025-08-29 | -2.54 |
| 2025-08-28 | -2.59 |
| 2025-08-27 | -2.55 |
| 2025-08-26 | -2.54 |
| 2025-08-25 | -2.54 |
| 2025-08-22 | -2.35 |
| 2025-08-21 | -2.26 |
| 2025-08-20 | -2.28 |
| 2025-08-19 | -2.30 |
| 2025-08-18 | -2.40 |
| 2025-08-15 | -2.46 |
| 2025-08-14 | -2.44 |
| 2025-08-13 | -2.46 |
| 2025-08-12 | -2.43 |
| 2025-08-11 | -2.40 |
| 2025-08-08 | -2.41 |